Roche India and Cipla Ltd have announced that the first batch of the antibody cocktail – Casirivimab and Imdevimab – is now available in India. They said that a second batch will be made available by mid-June. In total, they can potentially benefit 2,00,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients.
Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and Covid treatment centres. The Central Drugs Standards Control Organisation (CDSCO) had recently provided an Emergency Use Authorisation (EUA) for the antibody cocktail for Casirivimab and Imdevimab in India. It has also received a EUA in the US and several EU countries, the company said.
“Roche is deeply committed to supporting the ongoing efforts to combat the Covid-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of antibody cocktail (Casirivimab and Imdevimab) in India can help in minimising hospitalisation, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens,” said V Simpson Emmanuel, MD and CEO, Roche Pharma India.
Umang Vohra, MD & Global CEO Cipla said, “We are guided by our strong sense of responsibility to address unmet patient need and look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country”.
The antibody cocktail – Casirivimab and Imdevimab – is to be administered for the treatment of mild to moderate coronavirus disease 2019 in adults and pediatric patients of 12 years of age or older, weighing at least 40 kg who are confirmed to be infected with SARS-CoV-2 and who are at high risk of developing severe Covid-19 disease and do not require oxygen. It has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalisation and fatality by 70% and shortening the duration of symptoms by four days, the company said.